Clinical impact of molecular biomarkers in gliomas

Journal of Clinical Neuroscience

Volumn 22, Issue 3, 2015, Pages 437-444

  Siegal, Tali ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

Astrocytoma; Biomarkers; Glioma; Oligodendroglioma; Predictive; Prognostic

Indexed keywords

ATRX PROTEIN; B RAF KINASE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ATRX PROTEIN, HUMAN; BRAF PROTEIN, HUMAN; DNA HELICASE; DNA LIGASE; DNA METHYLTRANSFERASE; EGFR PROTEIN, HUMAN; MGMT PROTEIN, HUMAN; NUCLEAR PROTEIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ATRX GENE; BRAF GENE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CARCINOGENESIS; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; DRUG EFFICACY; EGFR GENE; FIAA1549 BRAF GENE; FUSION GENE; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; IDH GENE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MGMT GENE; MICROSATELLITE MARKER; NONHUMAN; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROMOTER REGION; PT53 GENE; REVIEW; SENSITIVITY AND SPECIFICITY; TP53 GENE; ASTROCYTOMA; BRAIN TUMOR; CHROMOSOME 19; GENETICS; MUTATION; OLIGODENDROGLIOMA; PROGNOSIS;

ASTROCYTOMA; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 19; DNA HELICASES; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; NUCLEAR PROTEINS; OLIGODENDROGLIOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 84923116932     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2014.10.004     Document Type: Review

References (82)

1. V.K. Ho, J.C. Reijneveld, and R.H. Enting Changing incidence and improved survival of gliomas Eur J Cancer 50 2014 2309 2318
2. F. Pignatti, M. van den Bent, and D. Curran Prognostic factors for survival in adult patients with cerebral low-grade glioma J Clin Oncol 20 2002 2076 2084
3. M. Weller, S.M. Pfister, and W. Wick Molecular neuro-oncology in clinical practice: a new horizon Lancet Oncol 14 2013 e370 e379
4. B. Freidlin, L.M. McShane, and E.L. Korn Randomized clinical trials with biomarkers: design issues J Natl Cancer Inst 102 2010 152 160
5. B. Freidlin, Z. Sun, and R. Gray Phase III clinical trials that integrate treatment and biomarker evaluation J Clin Oncol 31 2013 3158 3161
6. W. Wick, M. Platten, and C. Meisner Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Lancet Oncol 13 2012 707 715
7. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
8. M.E. Hegi, A.C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
9. R.M. Simon, S. Paik, and D.F. Hayes Use of archived specimens in evaluation of prognostic and predictive biomarkers J Natl Cancer Inst 101 2009 1446 1452
10. D.W. Parsons, S. Jones, and X. Zhang An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812
11. C. Hartmann, J. Meyer, and J. Balss Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas Acta Neuropathol 118 2009 469 474
12. H. Yan, D.W. Parsons, and G. Jin IDH1 and IDH2 mutations in gliomas N Engl J Med 360 2009 765 773
13. J.M. Bolduc, D.H. Dyer, and W.G. Scott Mutagenesis and Laue structures of enzyme intermediates: isocitrate dehydrogenase Science 268 1995 1312 1318
14. L. Dang, D.W. White, and S. Gross Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 2009 739 744
15. M.F. Amary, K. Bacsi, and F. Maggiani IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours J Pathol 224 2011 334 343
16. D.R. Borger, K.K. Tanabe, and K.C. Fan Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping Oncologist 17 2012 72 79
17. E.R. Mardis, L. Ding, and D.J. Dooling Recurring mutations found by sequencing an acute myeloid leukemia genome N Engl J Med 361 2009 1058 1066
18. S. Turcan, D. Rohle, and A. Goenka IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Nature 483 2012 479 483
19. W. Xu, H. Yang, and Y. Liu Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases Cancer Cell 19 2011 17 30
20. C. Hartmann, B. Hentschel, and W. Wick Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas Acta Neuropathol 120 2010 707 718
21. M.J. van den Bent, H.J. Dubbink, and Y. Marie IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group Clin Cancer Res 16 2010 1597 1604
22. M.J. van den Bent, C. Hartmann, and M. Preusser Interlaboratory comparison of IDH mutation detection J Neurooncol 112 2013 173 178
23. W. Wick, C. Hartmann, and C. Engel NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J Clin Oncol 27 2009 5874 5880
24. M. Weiler, and W. Wick Molecular predictors of outcome in low-grade glioma Curr Opin Neurol 25 2012 767 773
25. A. Lai, S. Kharbanda, and W.B. Pope Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin J Clin Oncol 29 2011 4482 4490
26. J. Beiko, D. Suki, and K.R. Hess IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection Neuro-Oncol 16 2014 81 91
27. D. Capper, S. Weissert, and J. Balss Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors Brain Pathol 20 2010 245 254
28. A. Korshunov, J. Meyer, and D. Capper Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma Acta Neuropathol 118 2009 401 405
29. O.C. Andronesi, O. Rapalino, and E. Gerstner Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate J Clin Investig 123 2013 3659 3663
30. N. Bertolino, C. Marchionni, and F. Ghielmetti Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: A phantom study Phys Med 30 2014 702 707
31. D. Krell, P. Mulholland, and A.E. Frampton IDH mutations in tumorigenesis and their potential role as novel therapeutic targets Future Oncol 9 2013 1923 1935
32. J. Popovici-Muller, J.O. Saunders, and F.G. Salituro Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo ACS Med Chem Lett 3 2012 850 855
33. F. Wang, J. Travins, and B. DeLaBarre Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation Science 340 2013 622 626
34. D. Rohle, J. Popovici-Muller, and N. Palaskas An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells Science 340 2013 626 630
35. M.J. Seltzer, B.D. Bennett, and A.D. Joshi Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1 Cancer Res 70 2010 8981 8987
36. M.M. Suzuki, and A. Bird DNA methylation landscapes: provocative insights from epigenomics Nat Rev Genet 9 2008 465 476
37. K. Uhlmann, K. Rohde, and C. Zeller Distinct methylation profiles of glioma subtypes Int J Cancer 106 2003 52 59
38. R.G. Verhaak, K.A. Hoadley, and E. Purdom Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110
39. H. Noushmehr, D.J. Weisenberger, and K. Diefes Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 2010 510 522
40. A.E. Pegg Repair of O(6)-alkylguanine by alkyltransferases Mutat Res 462 2000 83 100
41. M. Cankovic, M.N. Nikiforova, and M. Snuderl The role of MGMT testing in clinical practice: a report of the association for molecular pathology J Mol Diagn 15 2013 539 555
42. B.M. Ellingson, T.F. Cloughesy, and W.B. Pope Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas Neuroimage 59 2012 908 916
43. Levner I, Drabycz S, Roldan G, et al. Predicting MGMT methylation status of glioblastomas from MRI texture. In: Medical image computing and computer-assisted intervention: MICCAI. International Conference on Medical Image Computing and Computer-Assisted Intervention; 2009, vol. 12, pp. 522-30.
44. A. Romano, L.F. Calabria, and F. Tavanti Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status Eur Radiol 23 2013 513 520
45. A.A. Brandes, E. Franceschi, and A. Tosoni MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2008 2192 2197
46. C.K. Park, J. Kim, and S.Y. Yim Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients Neuro-Oncol 13 2011 195 202
47. M.R. Gilbert, M. Wang, and K.D. Aldape Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial J Clin Oncol 31 2013 4085 4091
48. W. Wick, C. Meisner, and B. Hentschel Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation Neurology 81 2013 1515 1522
49. A. Malmstrom, B.H. Gronberg, and C. Marosi Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial Lancet Oncol 13 2012 916 926
50. B. Wiestler, R. Claus, and S.A. Hartlieb Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective Neuro-Oncol 15 2013 1017 1026
51. V. Quillien, A. Lavenu, and M. Sanson Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients J Neurooncol 116 2014 487 496
52. L. Karayan-Tapon, V. Quillien, and J. Guilhot Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods J Neurooncol 97 2010 311 322
53. A. Christians, C. Hartmann, and A. Benner Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma PLoS One 7 2012 e33449
54. V. Fiano, M. Trevisan, and E. Trevisan MGMT promoter methylation in plasma of glioma patients receiving temozolomide J Neurooncol 117 2014 347 357
55. I. Lavon, M. Refael, and B. Zelikovitch Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades Neuro-Oncol 12 2010 173 180
56. J. Reifenberger, G. Reifenberger, and L. Liu Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p Am J Pathol 145 1994 1175 1190
57. R.B. Jenkins, H. Blair, and K.V. Ballman A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma Cancer Res 66 2006 9852 9861
58. G. Cairncross, M. Wang, and E. Shaw Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402 J Clin Oncol 31 2013 337 343
59. M.J. van den Bent, A.A. Brandes, and M.J. Taphoorn Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951 J Clin Oncol 31 2013 344 350
60. NCCN. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers, version 2. Available from: http://www.nccn.org; 2013.
61. B. Wiestler, D. Capper, and M. Sill Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma Acta Neuropathol 128 2014 561 571
62. M.N. Nikiforova, and R.L. Hamilton Molecular diagnostics of gliomas Arch Pathol Lab Med 135 2011 558 568
63. L. Liu, L.M. Backlund, and B.R. Nilsson Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas J Mol Med (Berl) 83 2005 917 926
64. R. Babu, and D.C. Adamson Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma Core Evid 7 2012 93 103
65. M. Nagane, F. Coufal, and H. Lin A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis Cancer Res 56 1996 5079 5086
66. C. Faulkner, A. Palmer, and H. Williams EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers Br J Neurosurg 2014 1 7 [Epub ahead of print]
67. K. Al-Nedawi, B. Meehan, and J. Micallef Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells Nat Cell Biol 10 2008 619 624
68. H. Shao, J. Chung, and L. Balaj Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy Nat Med 18 2012 1835 1840
69. M. Abedalthagafi, J.J. Phillips, and G.E. Kim The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas Mod Pathol 26 2013 1425 1432
70. D. Clynes, C. Jelinska, and B. Xella ATRX dysfunction induces replication defects in primary mouse cells PLoS One 9 2014 e92915
71. J. Schwartzentruber, A. Korshunov, and X.Y. Liu Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma Nature 482 2012 226 231
72. B. Wiestler, D. Capper, and T. Holland-Letz ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis Acta Neuropathol 126 2013 443 451
73. Y. Jiao, P.J. Killela, and Z.J. Reitman Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas Oncotarget 3 2012 709 722
74. X.Y. Liu, N. Gerges, and A. Korshunov Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations Acta Neuropathol 124 2012 615 625
75. T. Watanabe, S. Nobusawa, and P. Kleihues IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas Am J Pathol 174 2009 1149 1153
76. C. Hartmann, B. Hentschel, and M. Tatagiba Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 17 2011 4588 4599
77. P. Metellus, B. Coulibaly, and C. Colin Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis Acta Neuropathol 120 2010 719 729
78. Kieran, M.W. Targeting BRAF in Pediatric Brain Tumors. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology; 2014. p. e436-440.
79. S. Dahiya, R.J. Emnett, and D.H. Haydon BRAF-V600E mutation in pediatric and adult glioblastoma Neuro-Oncol 16 2014 318 319
80. T. Forshew, R.G. Tatevossian, and A.R. Lawson Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas J Pathol 218 2009 172 181
81. J.G. Cairncross, M. Wang, and R.B. Jenkins Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH J Clin Oncol 32 2014 783 790
82. R.J. Molenaar, D. Verbaan, and S. Lamba The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone Neuro-Oncol 16 2014 1263 1273